Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Cited by (1,010)

Items 401–500 of 1,010

1. The context-specific role of germline pathogenicity in tumorigenesis
   Preethi Srinivasan, Chaitanya Bandlamudi, Philip Jonsson, Yelena M. Kemel, Shweta S. Chavan, Allison L. Richards, Alexander V. Penson, Craig M. Bielski, Christopher John Fong, Aijazuddin Syed et al. · 2021 · Nature Genetics
2. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
   Morana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, Michael David Offin, Ken Suzawa, Ryma Benayed, Adam Jacob Schoenfeld, Andrew J. Plodkowski, John Thomas Poirier, Charles M. Rudin et al. · 2019 · Journal of Thoracic Oncology
3. Precision Oncology and the Universal Health Coverage System in Japan
   Hiromichi Ebi, Hideaki Bando · 2019 · JCO Precision Oncology
4. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
   Simon Heeke, Paul M Hofman · 2018 · Translational Lung Cancer Research
5. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
   Masaru Katoh · 2019 · Clinical Science
6. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
   Damien Reita, Lucile Pabst, Erwan Pencreach, Éric Guérin, Laurent Dano, Valérie Rimelen, Anne‐Claire Voegeli, Laurent D. Vallat, Céline Mascaux, Michèle Beau‐Faller · 2021 · Cancers
7. Chromatin remodellers as therapeutic targets
   Hayden A. Malone, Charles W.M. Roberts · 2024 · Nature Reviews Drug Discovery
8. TissGDB: tissue-specific gene database in cancer
   Pora Kim, Aekyung Park, Guangchun Han, Hua Sun, Peilin Jia, Zhongming Zhao · 2017 · Nucleic Acids Research
9. Molecular profiling and molecular classification of endometrioid ovarian carcinomas
   Paulina Cybulska, Arnaud Da Cruz Paula, Jill H. Tseng, Mario M. Leitão, Ali Bashashati, David D. Huntsman, Tayyebeh M. Nazeran, Carol A Aghajanian, Nadeem R. Abu‐Rustum, Deborah F. DeLair et al. · 2019 · Gynecologic Oncology
10. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
    Eileen Mary O'Reilly, Jaclyn Frances Hechtman · 2019 · Annals of Oncology
11. Telomerase Regulation: A Role for Epigenetics
    Fatma Doğan, Nicholas Robert Forsyth · 2021 · Cancers
12. Combinatorial strategies to target RAS-driven cancers
    Naiara Perurena, Lisa Situ, Karen M. Cichowski · 2024 · Nature reviews. Cancer
13. Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
    Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha · 2019 · The Oncologist
14. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
    Megan Greally, Joanne F. Chou, Walid Khaled Chatila, Matthew L. Margolis, Marinela Capanu, Jaclyn Frances Hechtman, Yaelle Tuvy, Ritika Kundra, Foysal Daian, Marc Ladanyi et al. · 2019 · Clinical Cancer Research
15. Anatomic position determines oncogenic specificity in melanoma
    Joshua M. Weiss, Miranda V. Hunter, Nelly M. Cruz, Arianna Baggiolini, Mohita M. Tagore, Yilun Ma, Sandra Misale, Michelangelo Marasco, Theresa Simon-Vermot, Nathaniel R. Campbell et al. · 2022 · Nature
16. Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening
    Kenneth Offit, Kaitlyn A. Tkachuk, Zsofia Kinga Stadler, Michael Francis Walsh, Hector J. Diaz-Zabala, Jeffrey D. Levin, Zoe Steinsnyder, Vignesh Ravichandran, Ravi Sharaf, Melissa Kristen Frey et al. · 2020 · Journal of Clinical Oncology
17. Cancer research needs a better map
    Jesse S. Boehm, Mathew J. Garnett, David J. Adams, Hayley E. Francies, Todd R. Golub, William C. Hahn, Francesco Iorio, James M. McFarland, Leopold Parts, Francisca Vázquez · 2021 · Nature
18. Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions
    Karin Schmelz, Joern Toedling, Matthew R. Huska, Maja C. Cwikla, Louisa-Marie Kruetzfeldt, Jutta Proba, Peter F. Ambros, Inge M. Ambros, Şengül Boral, Marco Lodrini et al. · 2021 · Nature Communications
19. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors
    Andrew Jeffrey Dunbar, Kelly L. Bolton, Sean M. Devlin, Francisco Sánchez-Vega, Jianjiong Gao, Jodi Victoria Mones, Jonathan Wills, Daniel Kelly, Mirko Farina, Keith B. Cordner et al. · 2020 · Blood
20. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
    Jennifer Y. Ge, Shaokun Shu, Mijung Kwon, Bojana Jovanović, Katherine C. Murphy, Anushree C. Gulvady, Anne Fassl, Anne C. Trinh, Yanan Kuang, Grace A. Heavey et al. · 2020 · Nature Communications
21. FGFR4: A promising therapeutic target for breast cancer and other solid tumors
    Kevin M. Levine, Kai Ding, Lyuqin Chen, Steffi Oesterreich · 2020 · Pharmacology & Therapeutics
22. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
    Christopher A. Febres‐Aldana, Jason C. Chang, Ryan N. Ptashkin, Yuhan Wang, Erika Gedvilaite, Marina K. Baine, William David Travis, Katia Ventura, Francis M. Bodd, Helena Alexandra Yu et al. · 2022 · Clinical Cancer Research
23. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer
    Guidantonio Malagoli Tagliazucchi, Anna J. Wiecek, Eloise Withnell, Maria Secrier · 2023 · Nature Communications
24. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer
    Smita Sihag, Geoffrey Yuyat Ku, Kay See Tan, Samuel C. Nussenzweig, Abraham Jing-Ching Wu, Yelena Yuriy Janjigian, David Randolph Jones, Daniela Molena · 2020 · Journal of Thoracic and Cardiovascular Surgery
25. Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
    Teng Gao, Ryan N. Ptashkin, Kelly L. Bolton, Maria Sirenko, Christopher Fong, Barbara G. Spitzer, Kamal N. Menghrajani, Juan Arango Ossa, Yangyu Zhou, Elsa Bernard et al. · 2021 · Nature Communications
26. Genomic profile of advanced breast cancer in circulating tumour DNA
    Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Sarah Hrebien, Claire Swift, Lucy Kilburn, Sarah Kernaghan, Laura Moretti et al. · 2021 · Nature Communications
27. Genomic landscape of endometrial carcinomas of no specific molecular profile
    Amir Momeni Boroujeni, Bastien Nguyen, Chad Vanderbilt, Marc Ladanyi, Nadeem R. Abu‐Rustum, Carol A Aghajanian, Lora H. Ellenson, Britta Weigelt, Robert A. Soslow · 2022 · Modern Pathology
28. Genomic mapping of metastatic organotropism in lung adenocarcinoma
    Harry B. Lengel, Brooke Mastrogiacomo, James G. Connolly, Kay See Tan, Yuan Liu, Cameron N. Fick, Elizabeth G. Dunne, Di He, Manendra B. Lankadasari, Baby Anusha Satravada et al. · 2023 · Cancer Cell
29. Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity
    Ian P. Winters, Shin‐Heng Chiou, Nicole K. Paulk, Christopher D. McFarland, Pranav V. Lalgudi, Rosanna K. Ma, Leszek Lisowski, Andrew J. Connolly, Dmitri A. Petrov, Mark A. Kay et al. · 2017 · Nature Communications
30. Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations
    Kevin Hauser, Christopher Negron, Steven K. Albanese, Soumya S. Ray, Thomas B. Steinbrecher, Robert Abel, John D. Chodera, Lingle Wang · 2018 · Communications Biology
31. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer
    Ethan S. Sokol, Yuxiong Feng, Dexter X. Jin, Ahmed Basudan, A.V. Lee, Jennifer M. Atkinson, Jun‐Jiang Chen, Philip J. Stephens, Garrett Michael Frampton, Piyush B. Gupta et al. · 2018 · Annals of Oncology
32. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
    Ming Zheng · 2022 · Journal for ImmunoTherapy of Cancer
33. Genetic Alterations of TRAF Proteins in Human Cancers
    Sining Zhu, Juan Jin, Samantha Gokhale, Angeli M. Lu, Haiyan Shan, Jian‐Jun Feng, Ping Xie · 2018 · Frontiers in Immunology
34. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy
    Lizza E.L. Hendriks, Étienne Rouleau, Benjamin Besse · 2018 · Translational Lung Cancer Research
35. Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma
    Guo Gord Zhu, Khédoudja Nafa, Narasimhan P. Agaram, Ahmet Zehir, Ryma Benayed, Justyna Sadowska, Laetitia A Borsu, Ciara Marie Kelly, William D. Tap, Nicola Fabbri et al. · 2019 · Clinical Cancer Research
36. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes
    Yuchen Xie, Merve Şahin, Sonali Sinha, Yufeng Wang, Amrita M. Nargund, Yang Lyu, Song Han, Yiyu Dong, James J.-D. Hsieh, Christina S. Leslie et al. · 2022 · Nature Cancer
37. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC
    Marina K. Baine, Christopher A. Febres‐Aldana, Jason C. Chang, Achim A. Jungbluth, Shenon Sethi, Cristina R. Antonescu, William David Travis, Min‐Shu Hsieh, Mee Sook Roh, Robert Homer et al. · 2022 · Journal of Thoracic Oncology
38. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
    James J. Harding, Sarina Anne Piha-Paul, Ronak H. Shah, Jessica Murphy, James M. Cleary, Geoffrey Ira Shapiro, David I. Quinn, Irene Braña, Víctor Moreno, Mitesh J. Borad et al. · 2023 · Nature Communications
39. The Evolving Genomic Landscape of Barrett’s Esophagus and Esophageal Adenocarcinoma
    Gianmarco Contino, Thomas L. Vaughan, David C. Whiteman, Rebecca Claire Fitzgerald · 2017 · Gastroenterology
40. Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients
    Takeshi Nagashima, Ken Yamaguchi, Kenichi Urakami, Yuji Shimoda, Sumiko Ohnami, Keiichi Ohshima, Tomoe TANABE, Akane Naruoka, Fukumi Kamada, Masakuni Serizawa et al. · 2019 · Cancer Science
41. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
    Alison Elizabeth Smith, Emanuela Ferraro, Anton Mikhailovich Safonov, Cristina Bernadó Morales, Enrique Javier Arenas, Qing Li, Amanda R. Kulick, Dara S. Ross, David B. Solit, Elisa de Stanchina et al. · 2021 · Nature Communications
42. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma
    Beryl Manning-Geist, Sushmita Gordhandas, Ying L. Liu, Qin C Zhou, Alexia E. Iasonos, Arnaud Da Cruz Paula, Diana L. Mandelker, Kara Long Roche, Oliver Zivanovic, Anna Maio et al. · 2022 · Clinical Cancer Research
43. Turning liabilities into opportunities: Off-target based drug repurposing in cancer
    Vinayak C. Palve, Yi Liao, Lily L. Remsing Rix, Uwe Rix · 2020 · Seminars in Cancer Biology
44. Mastermind: A Comprehensive Genomic Association Search Engine for Empirical Evidence Curation and Genetic Variant Interpretation
    Lauren M. Chunn, Diane C. Nefcy, Rachel W. Scouten, Ryan P. Tarpey, Gurinder Chauhan, Megan S. Lim, Kojo S.J. Elenitoba‐Johnson, Steven A. Schwartz, Mark J. Kiel · 2020 · Frontiers in Genetics
45. Massively parallel phenotyping of coding variants in cancer with Perturb-seq
    Ursu, Oana, Neal, James T., Shea, Emily, Thakore, Pratiksha I., Jerby-Arnon, Livnat, Nguyen, Lan, Dionne, Danielle, Diaz, Celeste, Bauman, Julia, Mosaad, Mariam Mounir et al. · 2022 · Nature Biotechnology
46. NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
    Fangfang Liu, Yuxuan Wei, Huan Zhang, Jizong Jiang, Peng Zhang, Qian Chu · 2022 · Frontiers in Oncology
47. <i>BRAF</i> -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
    Ciombor, Kristen K., Strickler, John H., Bekaii-Saab, Tanios S., Yaeger, Rona · 2022 · Journal of Clinical Oncology
48. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death‐Ligand 1 Blockade Responses
    Jihoon G. Yoon, Min Hwan Kim, Mi Jang, Hoguen Kim, Ho Kyoung Hwang, Chang Moo Kang, Woo Jung Lee, Beodeul Kang, Choong‐kun Lee, Min Goo Lee et al. · 2021 · Hepatology
49. Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis
    Goodwin G. Jinesh, Andrew Scott Brohl · 2022 · Signal Transduction and Targeted Therapy
50. Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions
    Ghoreyshi, Nima, Heidari, Reza, Farhadi, Arezoo, Chamanara, Mohsen, Farahani, Nastaran, Vahidi, Mahmood, Behroozi, Javad · 2025 · Discover Oncology
51. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies
    Jingyu Cao, Lijuan Chen, Heng Li, Hui Chen, Jicheng Yao, Shuo Mu, Wenjin Liu, Peng Zhang, Yu‐Wei Cheng, Binbin Liu et al. · 2019 · The Oncologist
52. Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
    Willard Wong, Edi Brogi, Jorge Sergio Reis-Filho, George Plitas, Mark E. Robson, Larry Norton, Monica Morrow, Hannah Yong Wen · 2021 · npj Breast Cancer
53. Genome-wide mapping of somatic mutation rates uncovers drivers of cancer
    Sherman, Maxwell A., Yaari, Adam U., Priebe, Oliver, Dietlein, Felix, Loh, Po-Ru, Berger, Bonnie · 2022 · Nature Biotechnology
54. <i>RASA1</i> and <i>NF1</i> are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition
    Hayashi, Takuo, Desmeules, Patrice, Smith, Roger S., Drilon, Alexander, Somwar, Romel, Ladanyi, Marc · 2018 · Clinical Cancer Research
55. Distinct Colorectal Cancer–Associated APC Mutations Dictate Response to Tankyrase Inhibition
    Emma M. Schatoff, Sukanya Goswami, María Paz Zafra, Miguel Foronda, Michael Shusterman, Benjamin I. Leach, Alyna Katti, Bianca Jay Diaz, Lukas E. Dow · 2019 · Cancer Discovery
56. Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects
    Amy P. Hsu, Ágnes Donkó, Megan E. Arrington, Muthulekha Swamydas, Danielle L. Fink, Arundhoti Das, Omar Escobedo, Vincent Robert Bonagura, Paul Szabolcs, Harry N. Steinberg et al. · 2019 · Blood
57. ACVR1 Function in Health and Disease
    José Antonio Valer, Cristina Sánchez‐de‐Diego, Carolina Pimenta-Lopes, José Luís Rosa, Francesc Ventura · 2019 · Cells
58. Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection
    Muyan Cai, Connor E. Dunn, Wenxu Chen, Bose S. Kochupurakkal, Huy Q. Nguyen, Lisa A. Moreau, Geoffrey Ira Shapiro, Kalindi Parmar, David Kozono, Alan D. D’Andrea · 2020 · Cell Reports
59. RHO GTPases in cancer: known facts, open questions, and therapeutic challenges
    Xosé R. Bustelo · 2018 · Biochemical Society Transactions
60. Current Status of Patient-Derived Ovarian Cancer Models
    Yoshiaki Maru, Yoshitaka Hippo · 2019 · Cells
61. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing
    Guan‐Tian Lang, Yi‐Zhou Jiang, Jinxiu Shi, Fan Yang, Xiaoguang Li, Yu‐Chen Pei, Chenhui Zhang, Ding Ma, Yi Xiao, Peng-Chen Hu et al. · 2020 · Nature Communications
62. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
    July Katherine Rodríguez, Jenny Ávila, Christian Diego Rolfo, Alejandro Ruíz-Patiño, Alessandro Russo, Luisa Ricaurte, Camila Ordóñez‐Reyes, Oscar G. Arrieta, Zyanya Lucía Zatarain-Barrón, Gonzalo Recondo et al. · 2021 · Oncology and Therapy
63. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
    Joris van de Haar, Xuhui Ma, Salo Ooft, Pim W. van der Helm, Louisa Rose Hoes, Sara Mainardi, David James Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora et al. · 2023 · Nature Medicine
64. Whole-Genome Sequencing in Cancer
    Eric Y. Stutheit-Zhao, Martin R. Jones, Steven J.M. Jones · 2018 · Cold Spring Harbor Perspectives in Medicine
65. Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion
    Kurtis D. Davies, Terry L. Ng, Adriana Estrada‐Bernal, Anh Tuan Le, Peter R. Ennever, D. Ross Camidge, Robert Charles Doebele, Dara L. Aisner · 2017 · JCO Precision Oncology
66. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma
    Frauke Goeman, Francesca De Nicola, Stefano Scalera, Francesca Sperati, Enzo Gallo, Ludovica Ciuffreda, Matteo Pallocca, Laura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi et al. · 2019 · Journal of Thoracic Oncology
67. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis
    Yan Li, Yiqi Ma, Zijun Wu, Fanxin Zeng, Bin Song, Yanrong Zhang, Jinxing Li, Su Lui, Min Cong Wu · 2021 · Frontiers in Immunology
68. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
    Louisa Rose Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien Joanna Zeverijn, Daphne Liselotte Van Der Velden, Joris van de Haar, Paul Roepman, Wendy W.J. de Leng, Anne M.L. Jansen, Erik D. van Werkhoven et al. · 2022 · Clinical Cancer Research
69. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma
    Eric Rios‐Doria, Amir Momeni Boroujeni, Claire Frances Friedman, Pier Selenica, Qin C Zhou, Michelle Ka Yan Wu, Antonio Marra, Mario M. Leitão, Alexia E. Iasonos, Kaled M. Alektiar et al. · 2023 · Gynecologic Oncology
70. RB constrains lineage fidelity and multiple stages of tumour progression and metastasis
    David M. Walter, Travis J. Yates, Miguel Ruiz-Torres, Caroline Kim-Kiselak, A. Andrea Gudiel, Charuhas G. Deshpande, Walter Wang, Michelle Cicchini, Kate L. Stokes, John W. Tobias et al. · 2019 · Nature
71. High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma
    Delia D’Avola, Carlos Villacorta-Martín, Sebastião N. Martins-Filho, Amanda J. Craig, Ismaïl Labgaa, Johann von Felden, Kimaada Allette, Antoinette Bonaccorso, Parissa Tabrizian, Boris Hartmann et al. · 2018 · Scientific Reports
72. Iron and lung cancer
    Yanbin Kuang, Qi Wang · 2019 · Cancer Letters
73. Inhibitors of BRAF dimers using an allosteric site
    Xiomaris M. Cotto-Rios, Bogos Agianian, Nadege Gitego, Emmanouil Zacharioudakis, Orsi Giricz, Yang Wu, Yiyu Zou, Amit K. Verma, Poulikos I. Poulikakos, Evripidis Gavathiotis · 2020 · Nature Communications
74. Evolution of metastasis: new tools and insights
    Philippe Gui, Trever Grant Bivona · 2021 · Trends in cancer
75. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
    Xiaoxiao Ma, Nadeem Riaz, Robert M. Samstein, Mark Andrew Lee, Vladimir Makarov, Cristina Valero, Diego Chowell, Fengshen Kuo, Douglas Robert Hoen, Conall W. R. Fitzgerald et al. · 2022 · Nature Genetics
76. Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers
    Meenakshi Anurag, Nindo B. Punturi, Jeremy Hoog, Matthew Neil Bainbridge, Matthew J. Ellis, Svasti Haricharan · 2018 · Clinical Cancer Research
77. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations
    Thereasa A. Rich, Karen L. Reckamp, Young Kwang Chae, Robert Charles Doebele, Wade Thomas Iams, Michael S. Oh, Victoria M. Raymond, Richard Burnham Lanman, Jonathan Wesley Riess, Thomas E. Stinchcombe et al. · 2019 · Clinical Cancer Research
78. New insights on human essential genes based on integrated analysis and the construction of the HEGIAP web-based platform
    Hebing Chen, Zhuo Zhang, Shuai Jiang, Ruijiang Li, Wanying Li, Chenghui Zhao, Hao Hong, Xin Huang, Hao Li, Xiaochen Bo · 2019 · Briefings in Bioinformatics
79. CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
    Yu Chen, Yingying Huang, Xuan Gao, Yi Li, Jing Lin, Lizhu Chen, Lianpeng Chang, Gang Chen, Yanfang Guan, Leong Kin Pan et al. · 2020 · Frontiers in Immunology
80. Systematic characterization of mutations altering protein degradation in human cancers
    Collin J. Tokheim, Xiaoqing Wang, Richard T. Timms, Boning Zhang, Elijah L. Mena, Binbin Wang, Cynthia Chen, Jun Ge, Jun Chu, Wubing Zhang et al. · 2021 · Molecular Cell
81. Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
    Alexander Edward Dela Cruz Drilon, M. Duruisseaux, Ji‐Youn Han, Masaoki Ito, Christina J. Falcon, Soo‐Ryum Yang, Yonina R. Murciano‐Goroff, Haiquan Chen, Morihito Okada, Miguel Ángel Molina‐Vila et al. · 2021 · Journal of Clinical Oncology
82. Molecular mechanisms underlying the development of neuroendocrine prostate cancer
    Shiqin Liu, Busola Ruth Alabi, Qingqing Yin, Tanya Ivanova Stoyanova · 2022 · Seminars in Cancer Biology
83. Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia
    Eric Wang, Jose Mario Bello Pineda, Won Jun Kim, Sisi Chen, Jessie Bourcier, Maximilian F. Stahl, Simon J. Hogg, Jan Philipp Bewersdorf, Cuijuan Han, Michael Singer et al. · 2022 · Cancer Cell
84. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer
    Caitlin A. McIntyre, Adrien Grimont, Jiwoon Park, Yinuo Meng, Whitney J. Sisso, Kenneth P. Seier, Gun Ho Jang, Henry S. Walch, Victoria G. Aveson, David J. Falvo et al. · 2024 · Cancer Cell
85. ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer
    Huang, Yun-Han, Hu, Jing, Chen, Fei, Lecomte, Nicolas, Basnet, Harihar, David, Charles J., Witkin, Matthew D., Allen, Peter J., Leach, Steven D., Hollmann, Travis J. et al. · 2020 · Cancer Discovery
86. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
    Biagio Ricciuti, Sasha Kravets, Suzanne Eleanor Dahlberg, Renato Umeton, Adem Albayrak, Safiya J. Subegdjo, Bruce Evan Johnson, Mizuki Nishino, Lynette Marie Sholl, Mark Magdi Awad · 2019 · Journal for ImmunoTherapy of Cancer
87. Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort
    Kanika S. Arora, Thinh Ngoc Tran, Yelena M. Kemel, Miika M. Mehine, Ying L. Liu, Subhiksha Nandakumar, Shaleigh A. Smith, Angela Rose Brannon, Irina Ostrovnaya, Konrad Hermann Stopsack et al. · 2022 · Cancer Discovery
88. Molecular principles underlying aggressive cancers
    Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang · 2025 · Signal Transduction and Targeted Therapy
89. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
    Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen H. Won, Sophie G. Shifman, Amanda R. Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena et al. · 2019 · Cancer Discovery
90. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer
    Johann Gout, Lukas Perkhofer, Mareen Morawe, Frank Arnold, Michaela Ihle, Stephanie Biber, Sebastian Lange, Élodie Roger, Johann Michael Kraus, Katja Stifter et al. · 2020 · Gut
91. A Performance Comparison of Commonly Used Assays to Detect RET Fusions
    Soo‐Ryum Yang, Umut Aypar, Ezra Y. Rosen, Douglas A. Mata, Ryma Benayed, Kerry A. Mullaney, Gowtham Jayakumaran, Yanming Zhang, Denise Frosina, Alexander Edward Dela Cruz Drilon et al. · 2020 · Clinical Cancer Research
92. The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy
    Amandeep Singh, Jeehoon Ham, Joseph William Po, Navin Niles, Tara Laurine Roberts, Cheok Soon Lee · 2021 · Cells
93. Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis
    Xuanwen Bao, Qiong Li, Jinzhang Chen, Diyu Chen, Chanqi Ye, Xiaomeng Dai, Yanfang Wang, Xin Li, Xiaoxiang Rong, Fei Cheng et al. · 2022 · Cancer Immunology Research
94. Mutational signatures are markers of drug sensitivity of cancer cells
    Jurica Levatić, Marina Salvadores, Francisco Fuster‐Tormo, Fran Supek · 2022 · Nature Communications
95. Cancer-associated mutations in DICER1 RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis
    Jeffrey Vedanayagam, Walid Khaled Chatila, Bülent Arman Aksoy, Sonali Majumdar, Anders J. Skanderup, Emek Demir, Nikolaus D. Schultz, Chris Sander, Eric C. Lai · 2019 · Nature Communications
96. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology
    Jessica J. Tao, Alison M. Schram, David Michael Hyman · 2017 · Annual Review of Medicine
97. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option
    Megan E. Buechel, Thomas J. Herzog, Shannon Neville Westin, Robert Louis Coleman, Bradley J. Monk, Kathleen N. Moore · 2019 · Annals of Oncology
98. Tumor mutational burden
    Lauren L. Ritterhouse · 2019 · Cancer Cytopathology
99. Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen
    Daichao Wu, D. Travis Gallagher, Ragul Gowthaman, Brian G. Pierce, Roy A. Mariuzza · 2020 · Nature Communications
100. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology
     Elio Adib, Amin H. Nassar, Sarah Abou Alaiwi, Stefan Groha, Elie W. Akl, Lynette Marie Sholl, Kesi Michael, Mark Magdi Awad, Pasi Antero Janne, Alexander Gusev et al. · 2022 · Genome Medicine